

1 F.W

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: July 28, 2004

Signature:

*Shawn P. Foley*  
(Shawn P. Foley)

Docket No.:  
BAKER 3.0-002  
CIP DIV CONT CONT  
(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:  
Broder et al.

Application No.: 10/800,990

Group Art Unit: 1614

Filed: March 15, 2004

Examiner: Richard L. Raymond

For: METHOD, COMPOSITIONS AND KITS FOR  
INCREASING THE ORAL  
BIOAVAILABILITY OF PHARMACEUTICAL  
AGENTS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. Copies of four newly cited publications (i.e., CL1, CM1, CN1, CO1) are enclosed. Copies of all other cited references were of record in Application Nos. 10/242,050 (pending), and/or U.S. Patent 6,610,735, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account

Application No.: 10/800,990

Docket No.: BAKER 3.0-002 CIP DIV CONT CONT


No. 12-1095.

Dated: July 28, 2004

Respectfully submitted,

By Shawn P. Foley  
Shawn P. Foley  
Registration No.: 33,071  
LERNER, DAVID, LITTENBERG,  
KRUMHOLZ & MENTLIK, LLP  
600 South Avenue West  
Westfield, New Jersey 07090  
(908) 654-5000  
Attorney for Applicant

506600\_I.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/800,990
				Filing Date	March 15, 2004
				First Named Inventor	Samuel Broder
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	1	of	3	Attorney Docket Number	BAKER 3.0-002 CIP DIV CONT CONT

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	US-5,112,817	05-12-1992	Fukazawa et al.	
	AB	US-5,114,951	05-00-1992	King	
	AC	US-5,118,493	06-00-1992	Kelley et al.	
	AD	US-5,124,330	06-00-1992	King	
	AE	US-5,124,338	06-00-1992	King	
	AF	US-5,124,339	06-00-1992	King	
	AG	US-5,166,207	11-00-1992	Smith	
	AH	US-5,208,238	05-00-1993	King	
	AI	US-5,300,282	04-00-1994	King	
	AJ	US-5,346,897	09-00-1994	King	
	AK	US-5,364,843	11-00-1994	King	
	AL	US-5,387,685	02-00-1995	Powell et al.	
	AM	US-5,395,610	03-00-1995	King	
	AN	US-5,405,843	04-11-1995	Fukazawa et al.	
	AO	US-5,416,091	05-00-1995	King	
	AP	US-5,438,072	08-00-1995	Bobee et al.	
	AQ	US-5,525,590	06-00-1996	Bollinger et al.	
	AR	US-5,646,176	07-00-1997	Golik et al.	
	AS	US-5,670,536	09-00-1997	Durr et al.	
	AT	US-5,750,561	05-00-1998	Bastart et al.	
	AU	US-5,968,972	10-00-1999	Broder et al.	
	AV	US-5,972,992	10-00-1999	Carver et al.	
	AW	US-6,004,927	12-00-1999	Benet al.	
	AX	US-6,096,331	08-00-2000	Desai et al.	
	AY	US-6,245,805	06-00-2001	Broder et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	EP 413828	11-00-1990			
	BB	WO 92/12132	07-00-1992			
	BC	WO 95/20980	08-00-1995			
	BD	WO 9727855	08-00-1997			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--




PTO/SB/08a/b (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	10/800,990
				Filing Date	March 15, 2004
				First Named Inventor	Samuel Broder
				Art Unit	1614
				Examiner Name	Not Yet Assigned
Sheet	2	of	3	Attorney Docket Number	BAKER 3.0-002 CIP DIV CONT CONT

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>	
	CA	Duverne, <i>et al.</i> , Antimicrobial Agents and Chemotherapy, 36(11):2462-2467 (1992)		
	CB	Vinceneux, <i>et al.</i> , International Journal of Clinical Pharmacology, Therapy and Toxicology, 24(3):153-158 (1986)		
	CC	Benet <i>et al.</i> , J. Cont. Release, Vol. 39, pp. 139-143 (1996)		
	CD	Brock <i>et al.</i> , Cancer Res., Vol. 55, pp. 459-462 (1995)		
	CE	Wils <i>et al.</i> , Biochem. Pharm., Vol. 48, pp. 1528-1530 (1994)		
	CF	Kloke <i>et al.</i> , Klin. Wochenschr., Vol. 63, pp. 1081-1082 (1985)		
	CG	Chang <i>et al.</i> , Clin. Pharm. Therap., Vol. 59, pp. 297-303 (1996)		
	CH	Chiu <i>et al.</i> , Proc. Of Am. Assoc. Pharm. Sci., Abstract PDD 7428 (Nov. 1995)		
	CI	Bal <i>et al.</i> , Proc. of Am. Assoc. Pharm. Sci., Abstract PDD 7459 (Nov. 1995)		
	CJ	Germann <i>et al.</i> , J. Bioenerg. Biomemb., Vol. 27, pp. 53-61 (1995)		
	CK	Joel <i>et al.</i> , Cancer Chemother. Pharmac., Vol. 37, pp. 125-133 (1995)		
	CL	Schinkel <i>et al.</i> , J. Clin. Invest., Vol. 96, pp. 1698-1705 (1995)		
	CM	Scheffer <i>et al.</i> , Nature Medicine, Vol. 1, No. 6, pp. 578-582 (1995)		
	CN	Lum <i>et al.</i> , Drug Resistance in Clin. Onc. and Hematology, Vol. 9, No. 2, pp. 319-336 (1995)		
	CO	Fracasso <i>et al.</i> , Proc. of ASCO, Vol. 14, Abstract 1585, p. 486 (1995)		
	CP	Bissey, Euro J. Cancer, Vol. 31A, Sup. 4, pp. S1-S6 (1995)		
	CQ	Leu <i>et al.</i> , Cancer Chem. Pharmac., Vol. 35, No. 5, pp. 432-436 (1995)		
	CR	Keogh <i>et al.</i> , N.E. J. Med., Vol. 333, No. 10, pp. 628-633 (1995)		
	CS	Leveque <i>et al.</i> , Anticancer Res. Vol. 15, pp. 331-336 (1995)		
	CT	Montaseri <i>et al.</i> , Pharm. Res., Vol. 12, No. 9, p. S-429, Abstract PPDM 8411 (1995)		
	CU	Muller, Proc. Nat. Acad. Sci., Vol. 91, pp. 13033-13037 (1994)		
	CV	Pouvelle <i>et al.</i> , J. Clin. Invest., Vol. 94, pp. 413-417 (1994)		
	CW	Schinkel <i>et al.</i> , Cell, Vol. 77, pp. 491-502 (1994)		
	CX	Fisher <i>et al.</i> , Proc. of ASCO, Vol. 13, Abstract 369, p. 144 (1994)		
	CY	Siegsmond <i>et al.</i> , J. Urol., Vol. 151, pp. 485-491 (1994)		
	CZ	Grant <i>et al.</i> , Cancer Res., Vol. 54, pp. 357-361 (1994)		
	CA1	Cresteil <i>et al.</i> , Cancer Res., Vol. 54, pp. 386-392 (1994)		
	CB1	Bartlett <i>et al.</i> , J. Clin. Onc., Vol. 12, No. 4, pp. 835-842 (1994)		
	CC1	Sikic <i>et al.</i> , Anticancer Drug Resistance: Adv. Molec. Clin. Res., pp. 149-165 (1994)		
	CD1	Kumar <i>et al.</i> , J. of Pharmac. and Exp. Therapeutics., Vol. 268, No. 3, pp. 1160-1165 (1994)		
	CE1	Lepage <i>et al.</i> , Current Op. in Neph. And Hypert., Vol. 2, pp. 735-743 (1993)		
	CF1	Lum <i>et al.</i> , Clin. Onc., Vol. 10, No. 10, pp. 1635-1642 (1992)		
	CG1	Loehrer, Seminars in Onc., Vol. 18, No. 6, Sup. 14, pp. 48-52 (1992)		
	CH1	Keller <i>et al.</i> , Int. J. Cancer, Vol. 51, pp. 433-438 (1992)		
	CI1	Hunter <i>et al.</i> , Pharma. Res. 10(5):743-749 (1993)		
	CJ1	Kobayashi, Proc. Ann. Meet. Am. Soc. Clin. Oncol. 15:A14889 (1996)		
	CK1	Harris <i>et al.</i> , Cancer Research, 54:4026-35 (1994)		
	CL1	Tsuruo, Jpn. J. Cancer Chemotherapy, 21(7):962:67, (1994) (English abstract only)		
	CM1	Baba <i>et al.</i> , Cancer Chemother. Pharmacol. 36(5):361-67(1995)		
	CN1	Terao <i>et al.</i> , J. Pharmacy & Pharmacol. 48:1083-1089(1996)		
	CO1	Sato, <i>et al.</i> , Cancer Chemother. Pharmacol.; 35(4):271-277 (1995)		

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<div>Substitute for form 1449A/B/PTO</div> <div><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b></div> <div><i>(Use as many sheets as necessary)</i></div>				<b>Complete if Known</b>	
				Application Number	10/800,990
				Filing Date	March 15, 2004
				First Named Inventor	Samuel Broder
				Art Unit	1614
				Examiner Name	Not Yet Assigned
				Attorney Docket Number	BAKER 3.0-002 CIP DIV CONT CONT
Sheet	3	of	3		

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--